E159 1030
adverse pathologic features. Eur Urol. In press.
https://doi.org/10. 1016/j.eururo.2017.03.036 .[2]
Austin PC, Steyerberg EW. Predictive accuracy of risk factors and markers: a simulation study of the effect of novel markers on different performance measures for logistic regression. Stat Med 2013;32:661–72.
[3]
Pepe MS, Kerr KF, Longton G, Wang Z. Testing for improvement in prediction model performance. Stat Med 2013;32:1467–82.[4]
Steyerberg EW, Pencina MJ, Lingsma HF, Kattan MW, Vickers AJ, Van Calster B. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. Eur J Clin Invest 2012;42:216–28.
Bruce J. Trock
a
R. Jeffrey Karnes
b,
*
a
James Buchanan Brady Urological Institute and Department of Urology,
Johns Hopkins School of Medicine, Baltimore, MD, USA
b
Department of Urology, Mayo Clinic, Rochester, MN, USA
*Corresponding author. Department of Urology, Mayo Clinic Rochester,
MN 55905, USA.
E-mail address:
karnes.r@mayo.edu(R.J. Karnes).
May 17, 2017
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) e 1 5 8 – e 1 5 9
e159